Raymond James Upgrades Tectonic Therapeutic to Strong Buy, Raises Price Target to $81

Benzinga Newsdesk www.benzinga.com Positive 93.5%

Neg 0% Neu 0% Pos 93.5%

Raymond James analyst Michael Freeman upgrades Tectonic Therapeutic (NASDAQ:TECX) from Outperform to Strong Buy and raises the price target from $76 to $81.